NASDAQ · OMER
Omeros Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OMER: Nov 12, 2026
Omeros Corporation Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Dec 2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Barchart · RTTNews · BNK Invest · Zacks- Barchart · Oct 19, 1:27 PM EDTStock Indexes Finish Sharply Lower as Tech Stocks PlungeThe S&P 500 Index ($SPX ) (SPY ) closed down by -1.09% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.50%. December E-mini S&P futures (ESZ26 ) fell -1.14%, and December E-mini…
- Barchart · Oct 16, 5:29 PM EDTStock Indexes Mostly Lower as Chipmaker Weakness PersistsThe S&P 500 Index ($SPX ) (SPY ) is down by -0.06% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.96%. December E-mini S&P futures (ESZ26 ) are down -0.10%, and December E-mini…
- Barchart · Oct 16, 5:29 PM EDTStocks are Mixed on Rotation Out of Chipmakers and AI StocksThe S&P 500 Index ($SPX ) (SPY ) is up by +0.03% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%. December E-mini S&P futures (ESZ26 ) are up +0.05%, and December E-mini…
- RTTNews · Oct 16, 8:37 AM EDTOmeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock Down(RTTNews) – Omeros Corporation (OMER) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the company's marketing authorization application for narsoplimab following a re-examination of
- RTTNews · Oct 16, 6:41 AM EDTOmeros: CHMP Issues Negative Opinion On Marketing Authorization Application For Narsoplimab(RTTNews) – Omeros (OMER) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the marketing authorization application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thr
- BNK Invest · Sep 28, 6:44 AM EDTAdd Up The Pieces: IHE Could Be Worth $116Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
- RTTNews · Sep 23, 8:25 AM EDTBiotech Stocks At 52-Week Highs – OMER +13%, TKNO +5%, BLFS, SDGR, INFU(RTTNews) – The following biotech stocks reached a 52-week high on September 22, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.
- Zacks · Aug 28, 12:00 PM EDTWhat Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 25, 9:55 AM EDTOmeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
- The Motley Fool · Aug 19, 8:13 PM EDTOmeros (OMER) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- BNK Invest · Aug 13, 3:19 PM EDTNotable Thursday Option Activity: DLO, AAP, OMERAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DLocal Ltd (Symbol: DLO), where a total of 23,399 contracts have traded so far, representing approximately 2.3 million underlying shares. That amounts to about 138.5% of
- RTTNews · Aug 13, 2:38 AM EDTOmeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise(RTTNews) – Omeros Corporation (OMER), a commercial-stage biotechnology company, on Wednesday reported second-quarter 2026 results that turned to profit, compared with a loss last year, aided by revenue growth driven by YARTEMLEA sales. In addition, the company provided an update
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Omeros Corporation from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.